Business
Medincell Publishes its Consolidated Half-Year Financial Results
MONTPELLIER, France, December 09, 2025--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): "We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leadin
About this update from Medincell Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/708e0c7a17097b8a386c229928cc5970"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q5yGoK1Yq964R9BRV6Z51A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/708e0c7a17097b8a386c229928cc5970","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6H5Y7cmt2.Jst5od3KM0lQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/708e0c7a17097b8a386c229928cc5970","width":1200,"height":200}},"lazy":false},{"type":"text","content":"(April 1st, 2025 - September 30, 2025)","length":38,"tagName":"p"},{"type":"text","content":"MONTPELLIER, France, December 09, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Christophe Douat, CEO of Medincell (Paris:MEDCL): "We are pleased with the company’s growth and momentum. We have entered the most transformative years in Medincell’s history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell’s growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leading the way, while further expanding and diversifying our pipeline and collaborations with leading pharmaceutical partners."","length":575,"tagName":"p"},{"type":"text","content":"Stéphane Postic, CFO of Medincell: "Revenues are growing and are expected to accelerate in the coming years with Olanzapine LAI. We have refined our investment plan to allocate resources strategically, with discipline and ambition. This approach is designed to create sustainable value and position Medincell for long-term success."","length":342,"tagName":"p"},{"type":"text","content":"Consolidated financial statements for the first half of the 2025-2026 fiscal year, ending September 30, 2025 (IFRS)","length":115,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total income: €14.1 million, +50% year-over-year","length":48,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Including revenues of €11...